US 12,129,220 B2
Pharmaceutical composition comprising aminoalkanoic acid derivative containing biphenyl group
Ki Duk Park, Seoul (KR); Jong Hyun Park, Seoul (KR); Hyeon Ji Kim, Seoul (KR); Ye Rim Lee, Seoul (KR); Siwon Kim, Seoul (KR); Ji Won Choi, Seoul (KR); Seul Ki Yeon, Seoul (KR); Jong-Seung Lee, Seoul (KR); Yong-Sun Bahn, Seoul (KR); Eunji Cheong, Seoul (KR); Kyung-Tae Lee, Seoul (KR); and Joohyeon Hong, Seoul (KR)
Assigned to AMTIXBIO CO., LTD., Seoul (KR)
Filed by AMTIXBIO CO., LTD., Seoul (KR)
Filed on Sep. 19, 2022, as Appl. No. 17/948,157.
Application 17/948,157 is a continuation of application No. 17/562,956, filed on Dec. 27, 2021, granted, now 11,479,526.
Application 17/562,956 is a continuation of application No. PCT/KR2020/008306, filed on Jun. 25, 2020.
Claims priority of application No. 10-2019-0075893 (KR), filed on Jun. 25, 2019.
Prior Publication US 2023/0053855 A1, Feb. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07C 231/02 (2006.01)
CPC C07C 231/02 (2013.01) 3 Claims
 
1. A pharmaceutical composition comprising as an active ingredient, a compound selected from the group consisting of:
1) 2-amino-N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)butanamide;
2) 2-amino-N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)pentanamide;
3) 2-amino-N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)hexanamide;
4) 2-amino-N-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)pentanamide;
5) N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(methylamino)butanamide;
6) N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(methylamino)pentanamide;
7) N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(methylamino)hexanamide;
8) N-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)-2-(dimethylamino)pentanamide;
9) 2-amino-N-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)pentanamide;
10) 2-amino-N-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)hexanamide;
11) 2-amino-N-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)pentanamide;
12) 2-amino-N-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methyl)hexanamide;
13) 2-amino-N-((4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)methyl)pentanamide;
14) 2-amino-N-((4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)methyl)hexanamide;
15) N-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)-2-(methylamino)pentanamide;
16) 2-(methylamino)-N-((4′-(trifuloromethyl)-[1,1′-biphenyl]-4-yl)methyl)pentanamide;
17) N-((3′,4′-dichloro-[1,1′-biphenyl]-4-yl)methyl)-2-(dimethylamino)pentanamide;
18) 2-amino-N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)butanamide;
19) 2-amino-N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)pentanamide;
20) 2-amino-N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)hexanamide;
21) 2-amino-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)butanamide;
22) 2-amino-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)pentanamide;
23) 2-amino-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)hexanamide;
24) 2-amino-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)butanamide;
25) 2-amino-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)pentanamide;
26) 2-amino-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)hexanamide;
27) 2-amino-N-(2-(3′,4′-difluoro-[1,1′-biphenyl]-4-yl)ethyl)pentanamide;
28) N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(methylamino)butanamide;
29) N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(methylamino)pentanamide;
30) N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(methylamino)hexanamide;
31) 2-(methylamino)-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)butanamide;
32) 2-(methylamino)-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)pentanamide;
33) 2-(methylamino)-N-(2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)hexanamide;
34) 2-(methylamino)-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)butanamide;
35) 2-(methylamino)-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)pentanamide;
36) 2-(methylamino)-N-(2-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)ethyl)hexanamide; and
37) N-(2-(3′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)-2-(dimethylamino)pentanamide, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.